Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Sees Large Growth in Short Interest

13 Jan 2026, 06:40 by Teresa Graham · The Cerbat Gem

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,057,055 shares, a growth of 954.2% from the December 15th total of 100,272 shares. Based on an average trading volume of 10,593,738 shares, the days-to-cover ratio is presently 0.1 days. Currently, 42.9% of the shares of the stock are sold short. Currently, 42.9% of the shares of the stock are sold short. Based on an average trading volume of 10,593,738 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Ekso Bionics has an average rating of “Hold” and an average target price of $10.50.

View Our Latest Research Report on Ekso Bionics

Insider Buying and Selling at Ekso Bionics

In other news, CEO Scott G. Davis sold 23,315 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $111,912.00. Following the completion of the sale, the chief executive officer owned 78,777 shares of the company’s stock, valued at $378,129.60. The trade was a 22.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jerome Wong sold 11,288 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $4.80, for a total transaction of $54,182.40. Following the transaction, the chief financial officer owned 26,009 shares of the company’s stock, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their position. The disclosure for this sale is available in the SEC filing. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ekso Bionics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Consolidated Portfolio Review Corp purchased a new position in shares of Ekso Bionics during the 3rd quarter worth $333,000. Citadel Advisors LLC acquired a new position in Ekso Bionics in the third quarter valued at about $198,000. Shay Capital LLC purchased a new position in Ekso Bionics during the third quarter worth about $67,000. Finally, Virtu Financial LLC purchased a new position in Ekso Bionics during the third quarter worth about $57,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $8.78 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $5.53 and a 200 day moving average price of $4.61. Ekso Bionics has a 12-month low of $2.73 and a 12-month high of $12.70. The stock has a market cap of $23.00 million, a P/E ratio of -1.55 and a beta of 0.71.

Ekso Bionics (NASDAQ:EKSO – Get Free Report) last posted its earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.45. The company had revenue of $4.23 million for the quarter, compared to analyst estimates of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. Sell-side analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

(Get Free Report)

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.